LivaNova PLC 10-Q Summary: Q2 2025
Business Context and Reporting Period
This summary covers LivaNova PLC's unaudited financial results for the quarterly period ended June 30, 2025. LivaNova is a global medical technology company operating in two primary segments: Cardiopulmonary (heart-lung machines, oxygenators) and Neuromodulation (VNS Therapy for epilepsy and depression, sleep apnea devices). The company is headquartered in London, UK, and trades on Nasdaq under the symbol LIVN.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $352.5 million | $318.6 million | $669.4 million | $613.5 million |
| Gross Profit | $239.0 million | $214.9 million | $455.2 million | $418.1 million |
| Operating Income | $54.2 million | $40.2 million | $102.8 million | $56.4 million |
| Net Income (Loss) | $27.2 million | $16.3 million | $(300.2) million | $(25.6) million |
| Diluted EPS | $0.50 | $0.30 | $(5.51) | $(0.47) |
| Cash & Equivalents | $593.6 million (as of June 30, 2025) | |||
| Total Debt Obligations | $430.6 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 10.7% in Q2 2025 compared to Q2 2024, driven by 14.7% growth in the Cardiopulmonary segment and 6.2% growth in Neuromodulation.
- SNIA Environmental Liability: The YTD 2025 net loss of $300.2 million is primarily due to a one-time $362.1 million expense recorded in Q1 2025 following an Italian Supreme Court ruling regarding environmental liabilities from the SNIA demerger. This non-cash charge significantly impacted the six-month results but did not affect Q2 operating income.
- Debt Reduction: In May 2025, the company repaid $200 million of its Term Facilities, resulting in a $2.7 million loss on debt extinguishment but reducing overall interest expense.
- Segment Performance: Cardiopulmonary segment income surged 60.0% in Q2 2025 to $31.4 million, aided by reduced litigation provisions for the 3T Heater-Cooler device. Neuromodulation segment income grew 2.2% to $56.0 million.
Guidance, Outlook, and Risks
- Clinical Updates:
- Epilepsy: Completed the CORE-VNS study, validating VNS Therapy effectiveness for severe focal seizures.
- Sleep Apnea: Announced 12-month top-line data from the OSPREY trial for the aura6000 system, showing a 65% responder rate.
- Depression: Initiated the process with CMS to seek reconsideration of Medicare coverage for VNS Therapy in treatment-resistant depression (TRD).
- Legal & Contingencies:
- SNIA Litigation: While the Supreme Court ruled on liability, the case was referred back to the Court of Appeal to determine final damages. The company has accrued $392.3 million as its best estimate.
- 3T Heater-Cooler Litigation: Approximately 60 claims remain; the company has accrued $15.4 million.
- Cybersecurity: Costs related to the November 2023 incident totaled $13.0 million through June 2025, with $9.6 million recovered via insurance.
- Regulatory: The company is evaluating the impact of the U.S. "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, which includes changes to R&D deductions and bonus depreciation.
Investor Verification Checklist
- SNIA Liability Finality: Verify the timeline and potential variance in the final damages award from the Italian Court of Appeal following the Supreme Court referral.
- Cash Flow Sustainability: Confirm that operating cash flow ($86.9 million YTD) remains sufficient to cover debt service and the accrued SNIA liability without further dilution or asset sales.
- CMS Coverage Decision: Monitor the outcome of the CMS reconsideration request for VNS Therapy in depression, which is critical for the Neuromodulation segment's growth.
- Debt Maturity: Review the status of the $287.5 million 2025 Notes due in December 2025 and the company's refinancing or repayment strategy.
- Accounting Revisions: Note the immaterial reclassification of employee costs between Cost of Sales and SG&A in prior periods, which has been corrected in this filing.